CorpechotC, CarratF, BahrA, ChretienY, PouponRE, PouponR. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology, 2005; 128:297–303.
7.
TandonP, RoweBH, VandermeerB, BainVG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol, 2007; 102:1528–1536.
8.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol, 2009; 51:237–267.
9.
ZeinCO, JorgensenRA, ClarkeBet al.Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology, 2005; 42:762–771.
